Erythromycin

As the earliest macrolide antibiotic applied in clinical practice, erythromycin reversibly binds to the 50S subunit of bacterial ribosomes, blocks the translocation process of peptidyl transferase, and inhibits bacterial protein synthesis. It has favorable antibacterial activity against Gram-positive bacteria, some Gram-negative bacteria and atypical pathogens. Clinically, it is mainly used to treat respiratory tract infections, skin and soft tissue infections, and urogenital system infections caused by sensitive bacteria. Meanwhile, it serves as an alternative anti-infective medication for patients with penicillin allergy, covers susceptible populations of all age groups including children and adults, and is one of the basic medications in the primary-level anti-infective diagnosis and treatment system.

At present, the global market size of erythromycin API is approximately USD 1.2 billion, with a compound annual growth rate maintained at around 3.2%. China is the world's largest producer and exporter of erythromycin API, with its production capacity accounting for more than 85% of the total global supply. Leading manufacturers are concentrated in industrial clusters in northwest China such as Ningxia and Inner Mongolia. With the advancement of the generic drug consistency evaluation work, the demand of domestic erythromycin preparation enterprises for high-quality APIs and supporting impurity reference substances continues to rise. Since 2023, the procurement volume of compliant API supporting materials that meet the standards of Chinese and US pharmacopoeias has increased by 17% year on year.

CATO can provide a full set of impurity reference substances for erythromycin API. All products are in stock, and meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA. They can directly meet the full-process R&D and production needs of pharmaceutical enterprises including impurity research, quality control, and generic drug declaration, helping enterprises shorten the compliance verification cycle and reduce R&D input costs.